Abstract: New fragments of the Factor VIII procoagulant protein (Factor VIIIC) are disclosed. These fragments have an Mr value of 88,000 d or 49,000 d or extend from amino acid residues 1974 to 2332 or 2052 to 2332. These fragments have use in the treatment of patients who have developed antibodies which inhibit Factor VIII.

Abstract: An aerosol spray dispenser of flowable pharmaceutical product is provided with a flotation stabilizing arrangement such that it will float in water in a stabilized erect position even when empty of product; a scale is associated with the dispenser so that the depth at which it floats can be read by comparing the position of the surface of the water in which it floats with graduations on the scale. The stabilizing action may be obtained by placing the dispenser in a floatable bottom-weighted vial, with the scale located in the exterior of the vial, and the combination of vial and dispenser then floated in water. In other embodiments the vial need not be used, in which case the dispenser itself may be bottom-weighted to assure its stabilized erect flotation and the scale placed on the exterior of the dispenser; or, a cap may be provided for the dispenser which is positioned on the dispenser while both are floated in the water, the cap being top-weighted so that the assembly floats stably upside-down.

Abstract: A process for the preparation of a viscosity-stable antacid composition containing an alginic acid salt comprising reacting an antacid material with said salt at elevated temperatures to form a reaction product and recovering said reaction product in stabilized form.

Abstract: This invention is directed to certain dibenzofurancarboxamides and dibenzofurancarboxamide acids and their use as 5HT.sub.3 antagonists having unique CNS, anti-emetic and gastric prokinetic activity void of any significant D.sub.2 receptor binding properties. Further, this invention relates to a process for the synthesis of stereoisomeric compounds having such CNS, anti-emetic and gastric prokinetic activity.

Abstract: Disclosed are novel peptide and pseudopeptide derivatives and phrmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.

Abstract: This invention relates to a series of bicyclic benzomonoazacyclic carboxamide compounds of the general formula: ##STR1## Where Z is tertiary amine, which are useful for the method of treating patients suffering from gastrointestinal disorders, and of pharmaceutical composition including an effective 5HT3 - antagonists amount of said compounds therein.

Abstract: This invention relates to quinolinyl-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

Abstract: Disclosed are novel amino acid derivatives of the formula: ##STR1## wherein X is H, amidino or ##STR2## Y is H, amino or ##STR3## Z is ##STR4## OR.sub.1 or a naturally occurring L-amino acid, bounded to the carbon atom at the .alpha.-amino position;R is alkyl, aryl or aralkyl;R.sub.1 and R.sub.2 are independently H, alkyl, aryl, aralkyl or allyl;m is 1 through 5;n is 0 through 4; andpharmaceutically acceptable salts thereof, that inhibit platelet aggregation and thrombus formation in mammalian blood.

Abstract: This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

Abstract: Disclosed are novel peptides and pseudopeptides and pharmaceutical compositions thereof containing certain amino acids and pharmaceutical compositions thereof that inhibit platelet aggregation and thrombus formation in mammalian blood.

Abstract: This invention relates to certain quinolinyl-benzoheterobicyclic compounds and their use as valuable pharmaceutical agents, particularly as lipoxygenase inhibitors and/or leukotriene antagonists and/or as mediator release inhibitors useful as anti-inflammatory and anti-allergic agents.

Abstract: This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

Abstract: A method for the preparation of a sustained release pharmaceutical composition comprising forming a fluidized ring of said particles and contacting said particles maintained suspended in said ring with a liquid composition containing a pharmaceutically active material and an alkali-soluble material.

Abstract: Disclosed are intranasal formulations comprising calcitonin and .sup..DELTA. -aminolevulinic acid in a pharmaceutically acceptable excipient.

Abstract: Disclosed are pharmaceutical compositions containing naphthoic acid derivatives and method of use for enhancing oxygen availability to mammailian tissue.

Abstract: This invention relates to substituted pyridooxazinone and naphtheridone pyridones which are useful as cardiotonic agents for the treatment of congestive heart failure, to methods for increasing cardiac contractility using said compounds, and pharmaceutical compositions including the same.

Abstract: A method of preparing von Willebrand Factor by disassociating it from a chaotropic agent in solution therewith and preferably treating the same under controlled temperature either in liquid or lyophilized form.

Abstract: Compounds useful for increasing cardiotonic contractility in humans or other animals and pharmaceutical compositions including these compounds are disclosed. The compounds have the general structure: ##STR1## where A is ##STR2## R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.9, and R.sub.10 are H, lower alkyl of 1-4 carbon atoms, phenyl, substituted phenyl, phenyl lower alkyl of 1-4 carbon atoms or substituted phenyl lower alkyl of 1-4 carbon atoms; and n is 0 or 1.

Abstract: Disclosed are novel 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids and esters derived therefrom and pharmaceutically acceptable salts thereof.Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.

Abstract: Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof.Phamaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.